Age-related macular degeneration
- PMID: 36996856
- DOI: 10.1016/S0140-6736(22)02609-5
Age-related macular degeneration
Abstract
Age-related macular degeneration is an increasingly important public health issue due to ageing populations and increased longevity. Age-related macular degeneration affects individuals older than 55 years and threatens high-acuity central vision required for important tasks such as reading, driving, and recognising faces. Advances in retinal imaging have identified biomarkers of progression to late age-related macular degeneration. New treatments for neovascular age-related macular degeneration offer potentially longer-lasting effects, and progress is being made towards a treatment for atrophic late age-related macular degeneration. An effective intervention to slow progression in the earlier stages of disease, or to prevent late age-related macular degeneration development remains elusive, and our understanding of underlying mechanistic pathways continues to evolve.
Copyright © 2023 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of interests RHG is a member of the advisory board of Bayer, Novartis, Apellis Pharmaceuticals, and Roche–Genentech; and reports honoraria from Apellis Pharmaceuticals, Bayer, and Novartis; consulting fees from Roche–Genentech; and receipt of loaned equipment from Zeiss. TGC reports being a director of the charitable NQ Eye Foundation and Kumu; payment for lectures from Medical Indemnity Protection Society; and salary support from Bayer through an unrestricted educational grant paid to the Centre for Eye Research Australia.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical